KCNN4 and glioma: Combined with the data of the present study, this might suggest that KCa3.1 targeting with TRAM-34 may sensitize glioma cells to radiation (or temozolomide) only under specific culture conditions and in selected glioma cell lines/cultures, speculatively preferentially in stem cell-enriching (serum-free) culture conditions.